|Mrs. Manju Deshbandhu Gupta||Chairman||5.1M||N/A||1944|
|Ms. Vinita D. Gupta||CEO & Exec. Director||173.73M||N/A||1968|
|Mr. Nilesh D. Gupta||MD & Exec. Director||81.78M||N/A||N/A|
|Mr. Ramesh Swaminathan||CFO & Exec. Director||43.75M||N/A||N/A|
|Mr. Rajvardhan V. Satam||Company Sec.||6.4M||N/A||N/A|
Lupin Limited, a pharmaceutical company, develops, produces, and markets a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) worldwide. It offers formulations for use in the therapeutic areas of cardiovascular, diabetology, asthama, pediatrics, central nervous system (CNS), gastro-intestinal, anti-infectives, nonsteroidal anti inflammatory drug therapy, anti-TB, and cephalosporins. The company also develops drug delivery technologies; and offers biosimilars for various therapies, such as oncology, anti-inflammatory, anti-virals, rheumatoid arthritis, endocrinology, diabetes, ophthalmology, and women's health. In addition, it engages in the novel drug discovery and development programs for use in the treatment of CNS disorders, oncology, immunology, pain, and metabolic disorders. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001 as a result of its amalgamation with Lupin Laboratories Limited. Lupin Limited was founded in 1968 and is based in Mumbai, India.
Lupin Limited’s ISS Governance QualityScore as of April 1, 2018 is 4. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 1; Compensation: 8.